An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion

Takao Watanabe; Yoshio Tokumoto; Masashi Hirooka; Yohei Koizumi; Fujimasa Tada; Hironori Ochi; Masanori Abe; Teru Kumagi; Yoshio Ikeda; Bunzo Matsuura; Kiyonori Takada; Yoichi Hiasa

doi:10.2169/internalmedicine.53.2131

CASE REPORTS

An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion

Takao Watanabe, Yoshio Tokumoto, Masashi Hirooka, Yohei Koizumi, Fujimasa Tada, Hironori Ochi, Masanori Abe, Teru Kumagi, Yoshio Ikeda, Bunzo Matsuura, Kiyonori Takada, Yoichi Hiasa

Author information

Takao Watanabe
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Yoshio Tokumoto
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Masashi Hirooka
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Yohei Koizumi
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Fujimasa Tada
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Hironori Ochi
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Masanori Abe
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Teru Kumagi
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Yoshio Ikeda
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Bunzo Matsuura
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
Kiyonori Takada
Postgraduate Clinical Training Center, Ehime University Graduate School of Medicine, Japan
Yoichi Hiasa
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan

Keywords: hepatitis B virus, human immunodeficiency virus, co-infection, tenofovir, seroconversion

JOURNAL OPEN ACCESS

2014 Volume 53 Issue 12 Pages 1343-1346

DOI https://doi.org/10.2169/internalmedicine.53.2131

Details

Abstract

The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion. An 18-year-old Japanese man with HIV and HBV co-infection presented to our hospital. His CD4 count was decreased, and TDF-based HARRT was started. At 30 months after initiation of therapy, HBsAg was not detected. At 36 months after initiation of therapy, HBsAb was detected. We conclude that TDF-based therapy is useful for the management of patients with HBV and HIV co-infection.

Corresponding author

Register with J-STAGE for free!